Tag: Mylotarg

Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy by enabling the selective delivery of cytotoxic agents to tumor cells, sparing healthy tissue. The design of ADCs allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently considered the most promising drug classes in oncology, with ongoing efforts to expand their use for non-oncological indications and in combination therapies.

Bristol Myers Squibb (BMS) has acquired Orum Therapeutics’ ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes.[1]

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed. Today, the standard of care for AML is treatment...

The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

A report published by Persistence Market Research (PMR), a U.S.-based full-service market intelligence firm specializing in syndicated research, shows that the global market for...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....

All products of the creative process are a reflection of the individual makeup of the inventors.  A painting by Mark Rothko looks like a...